Virginia F. Borges

Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer

Rashmi K. Murthy, Sherene Loi, Alicia Okines et al. · New England Journal of Medicine · 2019 · 1.3K citations · Full text

Medicine, Oncology, Pharmacology +12

Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial

Nancy U. Lin, Virginia F. Borges, Carey K. Anders et al. · Journal of Clinical Oncology · 2020 · 549 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

Charles E. Geyer, Judy E. Garber, Richard D. Gelber et al. · Annals of Oncology · 2022 · 447 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2+

Louis Fehrenbacher, Reena S. Cecchini, Charles E. Geyer et al. · Journal of Clinical Oncology · 2019 · 420 citations · Full text

Medicine, Oncology, Pharmacology +17

Prospective Study of Fertility Concerns and Preservation Strategies in Young Women With Breast Cancer

Kathryn J. Ruddy, Shari Gelber, Rulla M. Tamimi et al. · Journal of Clinical Oncology · 2014 · 396 citations · Full text

Medicine, Oncology, Fertility +13